Expression levels of potential ICP targets, such as HAVCR2, SIRPA, and CD209, were significantly higher in the high-risk than low-risk patient group in the current study, implying that differences in intratumoral bacteria in ovarian cancer are related to the sensitivity of patients receiving immunotherapy. Here, CD209 is linked to ovarian cancer.